Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACM-1
- Development stage
- Phase 1
- Lead developer
- ACM Biolabs
- Modality
- Small Molecules
- Administration
- Intravitreal
01
Overview
ACM-1 is a small molecule drug that functions as an inhibitor of vascular endothelial growth factor (VEGF). It was initially developed by Sun Yat-Sen University. The primary mechanism of action is the inhibition of VEGF, which plays a key role in angiogenesis and neovascularization. ACM-1 has been investigated for its potential to prevent and control ophthalmological neovascular diseases, particularly through intravitreal injection as an anti-VEGF therapy. Its development status is currently pending, with early phase 1 clinical trials conducted to explore its efficacy in treating pathologic neovascularization[1].
02
Targets
Beyond the preview
Go deeper on ACM-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACM-1.